# Randomization, allocation concealment, and interim-access firewall

Status: implemented as a deterministic synthetic operational-governance
fixture on 2026-08-26. It is not a clinical trial, proof of allocation
concealment, committee independence, GCP compliance, or clinical validation.

## Question

What minimum machine-checkable contract prevents a statistically declared
analysis from being undermined operationally by predictable assignments,
premature unblinding, unauthorized interim access, role collapse, repeated
looks, alpha-spending drift, inadequate committee quorum, recommendation
tampering, or sponsor override?

## Primary-source research map

### ICH E6(R3): Guideline for Good Clinical Practice

Sources:

- <https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf>
- <https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r3-guideline-good-clinical-practice-gcp-step-5_en.pdf>

The final Step 4/Step 5 guideline requires investigators to follow the trial's
randomization procedures. In an investigator-blinded trial, a treatment code
is broken only according to the protocol; emergency unblinding must be
available without undue delay for participant safety, and premature
unblinding must be promptly documented and explained.

Implemented consequence:

- the randomization method, strata, blocks, generator, assignment service,
  eligibility schema, concealment mechanism, roles, emergency policy and UTC
  lock are one versioned contract;
- the contract must be locked before the first synthetic enrollment;
- every assignment requires eligibility verification and an append-only opaque
  event identity;
- emergency unblinding requires an authorized role, minimum scope, attributed
  purpose, acknowledgement and reviewable chronology;
- no passing result is described as GCP implementation or conformance.

### ICH E9: Statistical Principles for Clinical Trials

Source: <https://database.ich.org/sites/default/files/E9_Guideline.pdf>

ICH E9 treats randomization and blinding as design techniques for reducing
bias, and requires interim analyses, their timing and stopping rules to be
planned before access to unblinded information. Repeated looks affect type-I
error and therefore cannot be operationally separated from the declared
statistical plan.

Implemented consequence:

- the operational package binds the exact statistical-package digest;
- two synthetic interim boundaries bind information fractions, cumulative
  alpha, efficacy, futility and safety thresholds;
- the boundary-plan digest is identical to the alpha-spending identity in the
  statistical package;
- duplicate or unplanned looks, changed information fraction, changed alpha or
  post-lock boundaries fail closed.

### FDA: Establishment and Operation of Clinical Trial Data Monitoring Committees

Sources:

- <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishment-and-operation-clinical-trial-data-monitoring-committees>
- <https://www.fda.gov/media/75398/download>

The final 2006 guidance states that unblinded interim comparisons generally
should be restricted to DMC members and the statistician performing the
analysis. It discusses written confidentiality procedures, independent
statistical preparation, closed sessions, committee composition and conflicts,
documented recommendations, and the risk that sponsor exposure can influence
trial management and interpretation.

Implemented consequence:

- sequence generation, enrollment, sponsor response, unblinded statistics,
  data management and committee review are closed synthetic roles;
- committee members carry authority, expertise, sponsor/investigator
  independence and conflict declarations;
- the clean fixture requires three voting members;
- only the unblinded statistician and committee may view comparative interim
  values; the sponsor receives a recommendation without numeric interim data;
- every access, recommendation and sponsor response is append-only and
  content-addressed.

## Implemented artifact

The versioned
`parkinsum.credibility-randomization-interim-firewall-package/1` provides:

1. concealed schedule and seed commitments without serializing either secret;
2. an eligibility-gated opaque assignment chain;
3. closed generation, enrollment, analysis, committee and sponsor roles;
4. an append-only minimum-scope access history;
5. a statistical-package-bound alpha-spending and boundary plan;
6. committee independence, conflict and quorum declarations;
7. recommendation, sponsor response, hold, correction and revocation states.

The independent gate applies 13 mutation families. Algorithm Observatory
renders randomization identity, concealment, role separation, access history,
interim boundaries, committee recommendation and adjudication as seven
separate lanes. It displays only commitment prefixes and bounded counts.

## Boundary

All identities, assignments, actors, authorities, committee members, clocks,
data cuts and results are fixed synthetic fixtures created in one local
process. Passing cannot prove that a real sequence was unpredictable, that
allocation remained concealed, that emergency unblinding was appropriate,
that people or organizations were independent, that a DMC operated correctly,
or that any trial, statistical, regulatory, benefit or safety conclusion is
valid.

## Researched next upgrade

Next queue item:
`credibility_adaptive_design_operating_characteristics_simulation_and_decision_rule_calibration_gate`.

This is distinct from the operational firewall. The current slice verifies who
may see accumulating data and whether a locked rule was followed; the next
slice will verify whether an adaptive rule has acceptable simulated operating
characteristics across prespecified data-generating scenarios.

Research sources:

- FDA final guidance, *Adaptive Design Clinical Trials for Drugs and Biologics*
  (2019):
  <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry>
- ICH E20 draft guidance, *Adaptive Designs for Clinical Trials* (2025):
  <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e20-adaptive-designs-clinical-trials>

The future gate should bind the design, adaptation algorithm, simulation code,
random-number generator, seeds, scenario distributions, nuisance parameters,
missingness, non-adherence, analysis model, repetitions and Monte Carlo error.
It should report type-I error, power, bias, interval coverage, sample-size and
selection probabilities over null, alternative and misspecified scenarios, and
kill decision-rule, timing, seed, scenario-omission and post-result adaptation
mutations. ICH E20 remains draft and not for implementation; it must remain
clearly labeled as research input rather than current regulatory requirements.
